Sterling provides oversight and reviews risks to protect the rights of research participants in clinical trials; for gene therapy research, additional oversight is provided by an institutional biosafety committee (IBC) to mitigate potential risks to laboratory and clinical staff, public health, and the environment. For optimal efficiency, IRBs and IBCs work together.
Sterling IRB has formed a strategic partnership with an expert provider in registering and administering IBCs. Sterling IRB will coordinate and manage the IRB/IBC collaboration for you, easing the oversight burden associated with gene transfer studies and ensuring your startup timelines are as efficient as possible.